Moderna (MRNA) Accumulated Expenses (2017 - 2026)

Moderna has reported Accumulated Expenses for 10 years, with the latest figure at $1.9 billion in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $1.9 billion, up 93.41% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.9 billion (up 93.41% YoY), and the FY2025 annual result was $1.4 billion, down 2.87% from the prior year.
• Accumulated Expenses held at $1.9 billion in Q2 2026, from $1.9 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.2 billion in Q3 2023 and troughed at $987.0 million in Q2 2025.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2022 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses surged 113.55%; it then tumbled 38.13% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $2.1 billion in 2022, then retreated by 14.42% to $1.8 billion in 2023, then retreated by 20.63% to $1.4 billion in 2024, then declined by 2.87% to $1.4 billion in 2025, then surged by 37.73% to $1.9 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.9 billion in Q2 2026, $1.9 billion in Q1 2026, and $1.4 billion in Q4 2025.